Despite the wide adoption of statins that are practically in the U.S. drinking water, there are still Americans who are not being treated with lipid-lowering therapies. So what's the answer? Dr. James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells the Chicago Tribune's Bruce Japsen about combination therapies and other new drugs being pursued by the pharmaceutical industry to manage cholesterol.